Literature DB >> 1359781

Instantaneous cardiac death in the posthospital period after acute myocardial infarction.

M O Sweeney1, A J Moss, S Eberly.   

Abstract

Sudden arrhythmic cardiac death is a major unresolved health problem, yet there is no agreement on the chronologic definition of sudden death. This retrospective study investigates the frequency distribution of the chronology of the terminal cardiac event in a large postinfarction population and identifies factors associated with instantaneous (< 1 minute) cardiac death. This study involved 229 patients enrolled in the Multicenter Diltiazem Post-infarction Trial who died during 2-year follow-up and had quantitative information on the chronology of the terminal event. Thirty-two percent of the cardiac deaths occurred instantaneously. Patients who died instantaneously were more likely (p < 0.05) to be men, to have a baseline ejection fraction < 0.40, and to have frequent (> or = 10/hour) and repetitive (> or = 3 in a row) ventricular ectopic complexes (VECs) on an ambulatory electrocardiogram than those who did not die instantaneously. Patients who died instantaneously received more digitalis and class IA antiarrhythmic agents and less beta blockers in the week before death than those dying noninstantaneously. Logistic regression analysis identified 3 independent factors that differentiated instantaneous from noninstantaneous death (relative risk; 95% confidence interval): frequent VECs (2.15; 1.11 to 4.17); digitalis (2.57; 1.31 to 5.06); and no beta blocker medication (2.90; 1.09 to 7.75). Instantaneous death (within 1 minute) was responsible for almost one third of the cardiac deaths that occurred in this postinfarction population. Frequent VECs, digitalis, and absence of beta-blocker therapy distinguished patients who died instantaneously from those who died noninstantaneously.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359781     DOI: 10.1016/0002-9149(92)90284-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  3 in total

1.  Digoxin and mortality in survivors of acute myocardial infarction: observations in patients at low and intermediate risk. The SPRINT Study Group. Secondary Prevention Reinfarction Israeli Nifedipine Trial.

Authors:  J Leor; U Goldbourt; S Behar; V Boyko; H Reicher-Reiss; E Kaplinsky; B Rabinowitz
Journal:  Cardiovasc Drugs Ther       Date:  1995-08       Impact factor: 3.727

2.  Digoxin and increased mortality among patients recovering from acute myocardial infarction: importance of digoxin dose. The SPRINT Study Group.

Authors:  J Leor; U Goldbourt; B Rabinowitz; H Reicher-Reiss; V Boyko; E Kaplinsky; S Behar
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

Review 3.  Digoxin is effective, but is it safe?

Authors:  F I Marcus
Journal:  Cardiovasc Drugs Ther       Date:  1993-12       Impact factor: 3.727

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.